01
Titer
Genome titer
qPCR or ddPCR measures vector genome concentration. It counts genomes but not whether particles are intact and infectious.
Custom Design, Production, and Functional Validation
Lentiviral Vector Development Service for Basic Research
Creative Biolabs designs, produces, and functionally validates custom lentiviral vectors for basic research, from a raw sequence or existing plasmid to sequence-verified, titered particles. Tell us your transgene, target cell type, and intended readout, and we define the vector design, pseudotype, production scale, and QC plan that match your experiment.
A lentiviral vector integrates its transgene into the host genome, providing stable expression in both dividing and non-dividing cells and supporting cargo up to roughly 8–10 kb. Creative Biolabs covers design, cloning and sequence verification, production and concentration, pseudotyping, and functional QC so you can move from a sequence to publication-grade data. Define the promoter, envelope, and payload, and confirm the titer and integration profile for your target cell before committing a full screen.
Vector design Promoter, envelope, and cassette architecture matched to your target cell and readout.
Production and titer Third-generation packaging with functional titer by qPCR and flow cytometry.
Functional QC Transduction efficiency, integration profile, and safety endpoints before you scale.
From Target Cell to Vector Choice
When does basic research need a custom lentiviral vector?
The vector only helps when its design matches the delivery and expression problem. These scenarios describe when a custom lentiviral approach is the right fit.
01 Stable overexpression in hard-to-transfect cells Neurons, primary cells, and organoids transduce poorly with plasmid reagents. A lentiviral vector provides integration-based, stable expression where transient methods fail.
02 Stable gene knockdown shRNA or miRNA cassettes delivered by lentivirus support long-term knockdown for lineage and loss-of-function studies where transient silencing is insufficient.
03 CRISPR/Cas9 and pooled screening All-in-one Cas9-sgRNA arrays or pooled libraries delivered at low MOI produce single-integrant cells for NGS-deconvolved screening.
04 Lineage tracing and long-term expression Integration makes the transgene heritable, supporting weeks-to-months monitoring without re-administration.
05 Immune-cell and CAR-T engineering Pseudotypes such as RD114 or BaEV-R enable transduction of primary T cells and CD34⁺ HSPCs without cytokine pre-activation.
06 In vivo and organoid transduction High-titer concentrated stocks and tissue-tropic envelopes support local administration in animal and cerebral-organoid models.
Core Service Modules
What does the lentiviral vector development workflow include?
Each module is scoped to your target and readout. Modules can be combined or selected independently.
01 Vector design and strategy
Design +
What we configure
- Promoter selection (CMV, EF1α, CAG, or tissue-specific options such as Syn1 or GFAP).
- Multi-cistronic architecture with 2A linkers, IRES, or all-in-one CRISPR arrays.
- Third-generation self-inactivating (SIN) LTRs and optional WPRE or insulator elements.
- Fluorescent and selection markers for sorting and enrichment.
Why it matters
- The promoter strength and envelope tropism determine which cells express your transgene.
- SIN LTRs reduce replication-competent lentivirus risk and promoter interference.
- Annotated plasmid files and a design rationale are provided before production.
02 Cloning and sequence verification
Build +
What we configure
- Golden-Gate and Gibson Assembly for seamless, scar-free multi-fragment builds.
- Flexible input from FASTA, a hand-drawn map, or an existing plasmid that needs sub-cloning.
- 100% Sanger coverage of the insert and junctions, with a signed sequence certificate.
Why it matters
- Zero-scar junctions prevent unwanted amino acids in fusion proteins.
- Sequence verification catches SNVs and indels before expensive downstream work.
03 Production and concentration
Produce +
What we configure
- Third-generation, suspension-adapted packaging with high-density transfection.
- Ultracentrifugation-coupled chromatography and endotoxin removal.
- Scale from pilot (1 mL) to pre-clinical volumes (10–50 mL).
Why it matters
- Reported titers range from roughly 1×10⁷ to 1×10⁹ TU/mL depending on scale.
- Endotoxin control (<0.1 EU/µg) supports in vivo use.
04 Pseudotyping and tropism
Tropism +
What we configure
- VSV-G for broad host range, Rabies-G for neurons, BaEV-R for CD34⁺ HSPCs, and RD114 for T cells.
- Custom glycoprotein swaps from a supplied envelope sequence.
Why it matters
- The envelope redirects tropism without changing the viral genome.
- A side-by-side transduction comparison guides the MOI for your cell line.
05 Functional titering
QC +
What we configure
- qRT-PCR (TU/mL) for integrated provirus copies.
- Flow-cytometry readout of percent-positive cells at defined MOIs.
Why it matters
- Dual-method validation flags discrepancies before you plate the experiment.
- A ready-to-use MOI calculator supports same-day plating.
06 Functional validation suite
Validate +
What we configure
- Transduction efficiency across a 10-point MOI matrix.
- Integration copy number by droplet digital PCR.
- Off-target scanning and a toxicity panel for in vivo readiness.
Why it matters
- Copy-number data supports clonal selection and biodistribution packages.
- A signed safety certificate formats cleanly for IACUC or IRB review.
Envelope and Delivery Options
Which pseudotype and production scale fit your experiment?
The envelope determines tropism; the scale determines volume and titer. These choices are made together with your target cell and readout.
VSV-G Broad host range
Scientific context The default envelope for screening panels and cells with unknown tropism.
Interpretation boundary Broad tropism is not cell-type specificity; confirm transduction in your target, not a proxy line.
Rabies-G Neuronal transduction
Scientific context Reported to improve neuron transduction relative to VSV-G in cortical and hippocampal cultures.
Interpretation boundary Neuronal benefit should be verified in the specific culture or in vivo region you study.
BaEV-R HSPC and primary T cells
Scientific context Unlocks human CD34⁺ HSPCs and primary T cells without cytokine pre-activation.
Interpretation boundary Entry is a first step; confirm stable expression and cell function after transduction.
RD114 T-cell and NK-cell targeting
Scientific context Engineered for human T-cell and NK-cell workflows, including CAR-T applications.
Interpretation boundary Tropism claims should be tested in the exact effector population and activation state.
Production scale Mini to Maxi
Scientific context Pilot (1 mL), midi (5 mL), and pre-clinical (10–50 mL) scales with increasing titer.
Interpretation boundary Titer is lot-specific; confirm functional titer on arrival rather than assuming the certificate value.
Custom pseudotyping Glycoprotein swap
Scientific context Supply an envelope sequence and the glycoprotein-swap pipeline produces a custom pseudotype.
Interpretation boundary A custom envelope requires its own transduction and packaging feasibility validation.
Quality and Validation Endpoints
Which measurements confirm a usable lentiviral vector?
Each endpoint answers a different question about your vector. Match the measurement to the decision you are making.
02
Potency
Functional titer
Flow cytometry measures percent-positive cells at defined MOIs, reflecting real transduction capacity.
03
Integration
Copy number
Droplet digital PCR against WPRE and a reference gene quantifies integration copies per diploid genome.
04
Safety
RCL testing
A qPCR assay screens for replication-competent lentivirus with high analytical sensitivity.
05
Purity
Endotoxin
Endotoxin removal and lot-release LAL data support in vivo use and vivarium acceptance.
06
Expression
Transduction efficiency
A 10-point MOI matrix identifies the working MOI that hits target positivity with minimal viability loss.
From Sequence to Data
How does a lentiviral vector project progress?
This sequence connects design with interpretable evidence. Acceptance criteria are agreed for each stage.
Design
01
Specify the Vector
Confirm promoter, payload, envelope, and safety elements against the target cell.
Build
02
Clone and Verify
Assemble the cassette and verify the full insert by Sanger sequencing.
Produce
03
Package and Concentrate
Transfect, harvest, concentrate, and deplete endotoxin to the agreed scale.
QC
04
Measure Titer and Safety
Run genome and functional titer, integration, and RCL or purity endpoints.
Deliver
05
Hand Off Data
Deliver frozen aliquots, certificates, and raw QC data for your experiment.
Titer is not transduction
A high genome titer does not guarantee functional transduction in your target cell. Confirm functional titer and expression in the intended model.
Limitations and Design Boundaries
What can limit a usable lentiviral vector?
Delivering the vector is not the same as answering the biological question. These boundaries should be explicit before committing resources.
-
Integration and insertional effects.
Integration-competent lentiviral vectors insert semi-randomly. Copy number, clonal composition, and insertional effects should be considered for the intended model.
-
Payload size.
Lentiviral vectors tolerate roughly 8–10 kb, but titer can decline with larger inserts. Check capacity before committing a large cassette.
-
Expression persistence.
Stable integration is not always desirable. For transient or dose-controlled studies, consider an inducible or integration-deficient design.
-
Cell-type boundaries.
A pseudotype that works in one cell line may not transduce your primary or organoid model. Confirm tropism empirically.
-
Production and controls.
Batch-to-batch variability and vector-associated effects require matched control vectors and independent preparations.
From Question to Evidence
Creative Biolabs Support
Select a service around the missing material or evidence in your study. Share the transgene, target cell, envelope preference, and intended readout so the technical discussion can define feasibility, inputs, and deliverables.
01 / VECTOR DESIGN
Lentiviral vector development
Configure the promoter, cassette architecture, safety elements, and markers for your target cell. Start with the transgene, cell type, and intended readout; feasibility review determines the design and validation plan.
Scope and outputs: Annotated plasmid files, design rationale, and sequence verification.
02 / PRODUCTION
Custom lentiviral vector production
Scale a validated construct with defined titer, purity, endotoxin, and QC. Distinguish pilot, midi, and pre-clinical volumes and confirm functional titer before downstream use.
Scope and outputs: Concentrated stock, lot certificates, and raw QC data.
03 / GENE SILENCING
Custom shRNA lentivirus
Deliver shRNA or miRNA cassettes for stable, long-term knockdown. Specify the target, transcript, and control hairpins; confirmation of knockdown is a separate readout from vector delivery.
Scope and outputs: shRNA vector design, production, and QC.
04 / GENE EDITING
Lentiviral vector design for gene editing
Configure lentiviral delivery of Cas9, sgRNA, or donor constructs. Separate delivery of editing components from the edited-cell phenotype in the study design.
Scope and outputs: Editing-vector design, production, and verification.
05 / TROPISM
Glycoprotein optimization
Select or engineer the envelope glycoprotein to redirect tropism. Confirm transduction in the exact target population rather than a proxy line.
Scope and outputs: Pseudotype design, production, and transduction comparison.
Selected Reading
Scientific context
Lentiviral Transduction
Naldini L, Blömer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science . 1996;272(5259):263-267. https://doi.org/10.1126/science.272.5259.263 .
Self-Inactivating Design
Zufferey R, Dull T, Mandel RJ, et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol . 1998;72(12):9873-9880. https://doi.org/10.1128/JVI.72.12.9873-9880.1998 .
Expression Control
Page A, Fusil F, Cosset FL. Toward tightly tuned gene expression following lentiviral vector transduction. Viruses . 2020;12(12):1427. https://doi.org/10.3390/v12121427 .
Project Planning
Questions about lentiviral vector development
Answers about study inputs, custom scope, reporting, and the next step after an inconclusive result.
Provide the transgene or construct, target cell type, intended readout, and envelope preference. Include the promoter, payload size, and any existing plasmid or sequence. If a pseudotype has not been selected, share the cell type so feasibility can be reviewed before design.
Yes. A project can focus on a single module, such as design, cloning, or production. Specify the material, verification requirements, and control relationships. The scope should distinguish construct generation from functional validation, with deliverables and acceptance criteria agreed separately.
VSV-G offers broad tropism, while Rabies-G, BaEV-R, and RD114 target neurons, HSPCs or primary T cells, and T/NK cells respectively. The choice should be confirmed empirically in your exact cell type. Share the target population and a side-by-side transduction comparison can guide the MOI.
Genome titer (TU/mL by qPCR or ddPCR) counts vector genomes, while functional titer (by flow cytometry) measures actual transduction. A high genome titer does not guarantee functional transduction, so both are reported and cross-checked.
Requirements depend on construct readiness, payload size, pseudotype, scale, and QC scope. Share available amounts and target milestones. The proposal states accepted materials, required work stages, deliverable formats, and factors that could change the schedule.
The result should be reported against the prespecified endpoints. Review the pseudotype, promoter, payload size, MOI, and cell condition before interpreting the mismatch. A different envelope, promoter, or expression design may be needed. Low transduction in one model does not invalidate the vector for another.
Start Your Project Today
Tell us about your project, and our experts will get back to you with a customized quote and proposal.
